Novabay Pharmaceuticals Inc IPO év
Mi az Novabay Pharmaceuticals Inc IPO év?
A IPO év az Novabay Pharmaceuticals Inc - 2007
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NYSEMKT-on cégekben a Novabay Pharmaceuticals Inc -hoz képest
Mit csinál Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
ipo év -hoz hasonló cégek Novabay Pharmaceuticals Inc
- G3 Exploration nak IPO év 2006 van
- Evolis SA nak IPO év 2006 van
- Unity Infraprojects nak IPO év 2006 van
- News Invest nak IPO év 2006 van
- AuStar Gold nak IPO év 2006 van
- Sky and Space Global nak IPO év 2006 van
- Novabay Pharmaceuticals Inc nak IPO év 2007 van
- Manas Resources nak IPO év 2008 van
- Mastech Digital Inc nak IPO év 2008 van
- MYR Inc nak IPO év 2008 van
- Dana Inc nak IPO év 2008 van
- American Water Works Co nak IPO év 2008 van
- Chromadex Corp nak IPO év 2008 van